GE HealthCare has added two AI-assisted tools to its Vscan Air handheld ultrasound system: Lung Guidance and AutoAS. They are meant to help clinicians assess patients with breathing problems at the point of care. Lung Guidance gives real-time prompts to help users position the probe and capture diagnostic-quality lung images. In validation testing, non-expert users succeeded 95.2% of the time, against 96.8% for experts. AutoAS estimates whether a patient has moderate-to-severe aortic stenosis, using standard 2D cardiac images from Vscan Air SL. It gives a confidence score with its estimate. Both tools have US Food and Drug Administration 510(k) clearance and CE marking. Existing customers with a valid Innovation Package are expected to receive them by the end of November 2026.

GE HealthCare has launched Allia Celeo, a ceiling-mounted image guiding system for interventional suites, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. The system pairs an extra-wide-bore C-arm with an AI-powered image chain and an on-screen digital twin that helps with positioning. The image chain adjusts acquisition parameters automatically to deliver consistent image quality at the lowest dose. It is also compatible with OnWatch Predict, which monitors remotely to anticipate downtime. Allia Celeo is the second new Allia system in under a year, after the floor-mounted Allia Moveo. It is CE marked, but its US Food and Drug Administration 510(k) clearance is pending, so it is not yet for sale in the US.

GE HealthCare raised its full-year outlook after third-quarter revenue rose 6.2% organically to $5.5 billion. Adjusted earnings per share climbed 25.1% to $1.34, and free cash flow reached $793 million. The company now expects about 4% organic revenue growth, adjusted earnings per share of $4.95 to $5.05, and free cash flow above $1.6 billion. Adjusted EBIT margin rose to 16.6%, and the dividend increased 14%. Pharmaceutical Diagnostics led growth, with organic revenue up 13.8% on contrast media and radiopharmaceuticals. The planned SOFIE Biosciences acquisition would add roughly 1% to annualised revenue and strengthen radiopharmaceutical supply. The backlog stood at $23.7 billion, up 12% from a year earlier.